Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | CCRL2 | O00421 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 7/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 4/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22731725 | 1.00 | KDM1A (0.47) | KDM1AMAOBMAPTCCRL2EPHX2 | |
| SCHEMBL22731828 | 1.00 | KDM1A (0.47) | KDM1AMAOBMAPTCCRL2EPHX2 | |
| SCHEMBL25039551 | 0.89 | EPHX2 (0.50) | KDM1AMAOBMAPTEPHX2ALDH1A1 | |
| SCHEMBL4169712 | 0.87 | EPHX2 (0.61) | EPHX2 | |
| SCHEMBL29665851 | 0.87 | KDM1A (0.44) | KDM1AMAOBMAPTCCRL2EPHX2 | |
| SCHEMBL24512915 | 0.87 | KDM1A (0.44) | KDM1AMAOBMAPTCCRL2EPHX2 | |
| SCHEMBL31205987 | 0.86 | KDM1A (0.49) | KDM1AMAOBMAPTEPHX2ALDH1A1 | |
| SCHEMBL25042382 | 0.85 | KDM1A (0.46) | KDM1AMAOBMAPTEPHX2ALDH1A1 | |
| SCHEMBL31206233 | 0.84 | MDM2 (0.49) | MAPTCCRL2ALDH1A1DRD2 | |
| SCHEMBL23720467 | 0.84 | KDM1A (0.49) | KDM1AMAOBMAPTEPHX2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11925651-B2 | TEAD inhibitors and uses thereof | Ikena Oncology, Inc. (US) | 2024-03-12 | — | — | US | disclosed |
| US-20230148061-A1 | TEAD INHIBITORS AND USES THEREOF | THE EHE FOUNDATION | 2023-05-11 | — | — | US | disclosed |
| US-11458149-B1 | TEAD inhibitors and uses thereof | Ikena Oncology, Inc. (US) | 2022-10-04 | — | — | US | disclosed |
| EP-3976192-A1 | TEAD INHIBITORS AND USES THEREOF | Ikena Oncology, Inc. (US) | 2022-04-06 | — | — | EP | disclosed |
| WO-2020243423-A1 | TEAD INHIBITORS AND USES THEREOF | Ikena Oncology, Inc. (US) | 2020-12-03 | — | — | WO | disclosed |
| WO-2020243423-A1 | TEAD INHIBITORS AND USES THEREOF | Ikena Oncology, Inc. (US) | 2020-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230148061-A1 | TEAD INHIBITORS AND USES THEREOF | TEAD2, TEAD3, TEAD4 | KDM1A 1093/4885MAOB 757/4885MAPT 507/4885 |
| US-11925651-B2 | TEAD inhibitors and uses thereof | TEAD2, TEAD3, TEAD4 | KDM1A 1093/4885MAOB 757/4885MAPT 507/4885 |
| US-11458149-B1 | TEAD inhibitors and uses thereof | TEAD2, TEAD3, TEAD4 | KDM1A 1093/4885MAOB 757/4885MAPT 507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.